Lv31
240 积分 2024-07-04 加入
The new IASLC grading system for invasive non‐mucinous lung adenocarcinoma is a more useful indicator of patient survival compared with previous grading systems
1天前
已完结
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
26天前
已完结
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
1个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
1个月前
已完结
Pembrolizumab as adjuvant therapy in non-small-cell lung cancer
1个月前
已完结
Pembrolizumab en adjuvant dans le cancer bronchique non à petites cellules
1个月前
已关闭
Impact of retinal fluid in patients with diabetic macular edema treated with anti-VEGF in routine clinical practice
1个月前
已完结
Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy
1个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
1个月前
已完结
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
1个月前
已完结
皖公网安备34019202002308
